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Abstract 
Purpose Clobazam (CLB) is metabolized by cytochrome P450 (CYP) 3A4 to yield N-desmethylclobazam 
(N-CLB), which is further inactivated by CYP2C19. The aim of this study was to retrospectively evaluate 
the relationship between CYP2C19 polymorphisms and the efficacy of low-dose, add-on CLB therapy in 
Japanese patients with epilepsy. 
Methods Fifty patients were divided into three groups according to their CYP2C19 polymorphism. CLB 
and N-CLB serum concentrations, and seizure frequency before and after starting CLB were analyzed.  
Results Extensive metabolizers (EMs, n = 11), intermediate metabolizers (IMs, n = 22), and poor 
metabolizers (PMs, n = 17) were included. Although the dose-normalized CLB serum concentrations 
were not significantly different, the dose-normalized N-CLB serum concentrations were significantly 
higher in PMs than in EMs or IMs. Seizure frequency was significantly decreased by the CLB therapy in 
PMs (p < 0.01), but not in EMs or IMs. CLB serum concentrations did not correlate with seizure 
reduction rate, but median N-CLB serum concentrations were significantly higher in patients with 
excellent seizure control (≧90% seizure reduction) compared to those with ≧50% seizure reduction or 
with < 50% seizure reduction (1103 ng/mL, 341 ng/mL and 570 ng/mL, respectively).  
Conclusions The efficacy of low-dose CLB therapy was significantly influenced by CYP2C19 
polymorphisms. Ideally, CLB therapy should be started with a low dose (2.5 mg/d), and dosage increased 
until N-CLB serum concentration reaches 1100 ng/mL, or until the desired effect is acquired, a 
recommendation that is particularly important for PMs. 
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Introduction 
Clobazam (CLB) was approved in France in 1974 and is currently available in over 100 countries 
[1]. It has been on the market since 2000 in Japan and was licensed for Lennox-Gastaut syndrome in the 
United States in 2011. Other benzodiazepines such as diazepam, clonazepam, and lorazepam are 
1,4-benzodiazepines, yet the efficacy of CLB, a 1,5-benzodiazepine, seems superior to that of the 
1,4-benzodiazepines [2-4]. In an add-on trial, CLB administration was proven to be effective as an 
adjuvant therapy for epilepsy [2]. CLB has been used mainly as an add-on drug throughout the world 
[5-7].  
CLB is metabolized primarily in the liver by cytochrome P450 (CYP) 3A4 into a 
pharmacologically active metabolite, N-desmethylclobazam (N-CLB); N-CLB is further metabolized into 
an inactive metabolite by CYP2C19 [8]. CLB and N-CLB have been reported to interact with other 
antiepileptic drugs [9-14]. CLB concentrations are decreased by the presence of carbamazepine, 
phenytoin, or phenobarbital, which are characterized as CYP inducers, inducing CYP3A4 as well [9-11]. 
N-CLB concentrations were reported to increase when CLB was concurrently administered with 
carbamazepine or phenytoin, which presumably occurs because the concurrently administered drugs 
induce the metabolism of CLB to N-CLB [11-13]. In contrast, zonisamide and topiramate are reported to 
be CYP2C19 inhibitors [14,15] and can increase N-CLB concentrations. 
Not only the co-administrated drugs but also polymorphic recessive mutations at the CYP2C19 
gene, which cause the poor metabolizer (PM) phenotype [16], are known to affect the metabolism of CLB. 
The N-CLB/CLB concentration ratio was dependent on the number of mutated alleles of CYP2C19 (gene 
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dose effect), and this ratio may be a valuable parameter to screen for patients at risk for side effects 
[17,18]. The frequency of CYP2C19 PM varies across races, and is higher in Asian populations (18–23%), 
including Japanese, than in Caucasians (2–5%) [16,19]. Two defective CYP2C19 alleles (CYP2C19*2 
and CYP2C19*3) have been found to account for more than 99% of Asian PM alleles, and allele 
frequencies for CYP2C19*2 and CYP2C19*3 were 0.31 and 0.10, respectively, in the Japanese 
population [20].  
CLB is usually administered at a daily dose of 10-40 mg. However, we previously reported that 
the low-dose (2.5 mg/d), add-on CLB therapy is effective in some adult patients with refractory epilepsy 
and that its degree of effectiveness is correlated with serum concentrations of N-CLB [21]. However, 
information on the effect of CYP2C19 polymorphisms on the clinical efficacy and therapeutic range of 
N-CLB is limited. The objective of this study was to retrospectively analyze the effect of CYP2C19 
genotypes on the pharmacokinetics of CLB and N-CLB, as well as the clinical efficacy in the Japanese 
adult patients with epilepsy. We clarified the relationship between CYP2C19 polymorphisms and clinical 
efficacy in the low-dose (initial dose, 2.5 mg/d), add-on CLB therapy, and also defined a clinically 
effective serum concentration range for N-CLB. 
 
Materials and Methods 
Subject and study design 
This retrospective study included 50 adult patients (24 men and 26 women; age range, 18–72 
years) with epilepsy who had been treated at the epilepsy clinics of the Department of Neurology, Kyoto 
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University Hospital from July 2006 to September 2011. These patients had been receiving the same 
dosage of CLB regularly for at least one month. This study was conducted according to the Declaration of 
Helsinki and its amendments, and was approved by the Kyoto University Graduate School of Medicine, 
Faculty of Medicine, and the Kyoto University Hospital Ethics Committee. All patients provided written 
informed consent before undergoing the genotyping test. 
The steady state dose was individually decided as follows. As an add-on therapy, CLB was started 
in patients with 2.5 mg/d at bedtime, with both efficacy and tolerability observed at least four weeks later. 
In this study, the tolerability is defined as the state that patients could keep the same dose of medication 
with tolerable adverse reactions, such as slight sleepiness that their quality of life was not significantly 
impaired. Until the patients had improved seizure control with tolerable adverse reactions, the dose was 
increased by 2.5 mg/d every at least four weeks. Once better seizure control was achieved, the same dose 
was retained as the steady state dose. If intolerable side effects such as sleepiness, excessive drooling, or 
drowsiness occurred, the dose was decreased by 2.5 mg/d or finally stopped, depending on the clinical 
state. Throughout those periods, other antiepileptic drugs were maintained at the same dose. 
 
Pharmacokinetics 
     Serum drug concentrations in 50 samples were retrospectively analyzed. These blood samples were 
collected during the outpatient visit in the morning after steady state for the optimal dose had been 
achieved. Concentrations of CLB and N-CLB were measured with high-performance liquid 
chromatography (HPLC) with UV detection by a validated external commission company (SRL Inc., 
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Tokyo, Japan). The lower limit of quantification was 10 ng/mL for both drugs. The intra- and inter-day 
variation of the analysis was 3.0% and 6.0%, respectively. Samples with concentrations of CLB under the 
lower limit of detection (10 ng/mL) because of low dosage were included during in the analysis and 
replaced with the value of 5 ng/mL (n=5) [22]. Two patients who did not have CLB or N-CLB 
concentration datum, but were evaluated the clinical efficacy were included in the study. We also 
collected information on concurrent therapy with antiepileptic drugs, carbamazepine, phenytoin, valproic 
acid, zonisamide, phenobarbital, clonazepam, gabapentin, topiramate, lamotrigine, and levetiracetam, 
from the patients’ medical records. All patients were administering 1–5 other antiepileptic drugs, in 
various combinations. Patients were classified as those who received CYP inducers (phenytoin, 
carbamazepine, or phenobarbital) and those who received CYP2C19 inhibitors (zonisamide or 
topiramate) [14,15,23]. Each patient was not receiving any drugs except antiepileptics which potentially 
affect the pharmacokinetics of CLB, such as CYP3A4 inhibitors or CYP2C19 inhibitors. 
 
Genotyping 
Genomic DNA was isolated from whole blood samples, and the polymerase chain reaction 
restriction fragment length polymorphism method was used to analyze CYP2C19*2 and CYP2C19*3 
mutations [24,25]. The patients were divided into three groups according to their CYP2C19 
polymorphisms: homozygous extensive metabolizers (EMs) (*1/*1), intermediate metabolizers (IMs) 
(*1/*2 or *1/*3), and poor metabolizers (PMs) (*2/*2, *3/*3 or *2/*3). The characteristics of patients 
distributed into these three groups were compared. 
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Evaluation of epilepsy 
In accordance with the epilepsy classification in 2010 as much as possible to apply [26], 33 cases 
were classified as partial epilepsy with multiple etiologies (being equivalent to 24 cases as temporal lobe 
epilepsy and 9 as extra-temporal lobe epilepsy in 1989 classification [27]), 17 patients as with epilepsy 
with generalized tonic–clonic seizures alone or generalized epilepsy with multiple etiologies (being 
equivalent to symptomatic generalized epilepsy or idiopathic generalized epilepsy in 1989 classification 
[27]). With regard to seizure classification [26], 9 and two patients had two or three types of seizures, 
respectively, and the others had one type of seizure: 43 patients had focal seizures (being equivalent to 27 
had complex partial seizures, and 16 had simple partial seizures in 1981 classification [28]), and 20 
patients had generalized tonic-clonic seizures.  
Baseline seizure frequency and seizure frequency during CLB therapy was determined by counting 
the number of seizures in the three months immediately prior to administration of CLB, and after 
reaching the optimal dose of CLB, respectively. Patients whose seizure frequency was more than one per 
month during the baseline period, despite receiving the maximum tolerable dose of appropriate 
antiepileptic drugs in various combinations, were judged as having intractable seizures with the rest 
characterized as having tractable seizures. Clinical efficacies were evaluated based upon seizure control. 
The patients whose seizure frequency was reduced by less than 50%, or whose CLB administration was 
withdrawn were classified into the “< 50% seizure reduction” group. The patients whose seizure 
frequency was reduced by more than 50%, but less than 90% were classified into the “≧ 50% seizure 
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reduction” group. The patients whose seizure frequencies were reduced by more than 90%, were 
classified into the “≧ 90% seizure reduction” group. The physician-in-charge, who was blinded to the 
results of CYP2C19 polymorphisms, evaluated clinical outcomes in each patient. Three patients (one 
from each group) who suffered from psychogenic seizures were excluded from the analysis of seizure 
frequency at the baseline and clinical efficacy. 
 
Statistical analysis 
Statistical analyses were performed using Prism6 software (GraphPad Software, San Diego, CA, 
USA). Differences between the three groups were analyzed using the Kruskal-Wallis test, followed by 
Dunn’s multiple comparison test. Frequencies of observation among the three CYP2C19 phenotypes were 
analyzed using the chi-square test. The CYP2C19 genotype frequency of the study patients was analyzed 
with the Hardy-Weinberg principle using the chi-square test. Changes in seizure frequency before and 
after initiation of CLB therapy were analyzed by the paired t-test. A p value less than 0.05 was considered 
to be statistically significant. 
 
Results 
Fifty patients were divided into three groups according to their CYP2C19 phenotype: EMs (n = 
11), IMs (n = 22), and PMs (n = 17) (Table 1). There were no significant differences between the three 
groups in terms of gender, age, epilepsy classification, seizure type, seizure frequency at baseline, or 
following co-administration of a CYP inducer or CYP2C19 inhibitor. The body weight and CLB dose 
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were significantly different between the three phenotypes, and the CLB dose per body weight in PMs was 
less than half in EMs, although this difference did not reach statistical significance. The genotype 
frequency of CYP2C19 in the 50 patients was inconsistent with the Hardy-Weinberg equilibrium based on 
the allele frequency of CYP2C19*2 and CYP2C19*3 [20] (p < 0.01). 
The median time from the start of CLB administration to the measurement of serum concentration 
was 12 months (1-69 months), 17 months (1-75 months) and 5 months (1-235 months) in EMs, IMs and 
PMs, respectively. The serum concentrations of CLB and N-CLB were compared between the three 
groups (Table 1). N-CLB concentrations were higher in PMs (median, 1071 ng/mL) than in IMs (median, 
632 ng/mL) or EMs (median, 290 ng/mL), although no significant differences in CLB concentration were 
observed between the three groups. To adjust the effect of dose differences among the groups, the ratio of 
serum concentration to CLB dose (C/D ratio) for CLB and N-CLB, and the serum concentration ratio of 
N-CLB to CLB (N-CLB/CLB ratio) were calculated for the three groups (Fig. 1). The N-CLB C/D ratio 
was significantly higher in PMs (median, 16300 (ng/mL)/(mg/kg/d)) than in EMs (median, 1760 
(ng/mL)/(mg/kg/d)) or IMs (median, 5640 (ng/mL)/(mg/kg/d)), while the CLB C/D ratio did not 
significantly differ between the three groups. The N-CLB/CLB ratio was also significantly higher in PMs 
(median, 63.5) than in EMs (median, 5.4) or IMs (median, 15.3). 
To evaluate the effect of co-administered drugs on the pharmacokinetics of CLB, the patients were 
divided into 4 groups: patients who were not administered CYP inducers nor CYP2C19 inhibitors, 
patients administered CYP2C19 inhibitors without CYP inducers, patients administered CYP inducers 
without CYP2C19 inhibitors, and patients administered both CYP inducers and CYP2C19 inhibitors. The 
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CLB C/D ratio was significantly lower in the group administered CYP inducers compared to the group 
that was administered neither CYP inducers nor CYP2C19 inhibitors, or to the group administered only 
CYP2C19 inhibitors. There were no significant differences in the N-CLB C/D ratio between the 4 groups 
(Fig. 2), while within each group, the N-CLB C/D ratio in PMs tended to be higher than that in EMs or 
IMs. 
To evaluate the clinical effect of CLB, changes in seizure frequency before and after starting CLB 
therapy were analyzed for the three CYP2C19 phenotypes (Fig. 3). Seizure frequency was decreased in 
all PMs except one patient. There were no significant changes in seizure frequency for either EMs or IMs. 
The clinical effect was evaluated by determining the seizure-reduction rate in the three months 
prior to and following CLB add-on therapy (Fig. 4). Patients were divided into < 50％-reduction, ≧ 
50%-reduction, and ≧ 90%-reduction groups, and concentrations of CLB and N-CLB were compared 
between the three groups. N-CLB concentration was significantly higher in the ≧ 90%-reduction group 
(median value: 1103 ng/mL) than in the <50% or the ≧50%-reduction groups (median value: 570 ng/mL 
and 341 ng/mL, respectively). There were no significant differences in CLB concentration between these 




CLB is metabolized mainly by CYP3A4, and its active metabolite N-CLB is further inactivated by 
CYP2C19. It has been reported that the antiepileptic potency of N-CLB is 40% of CLB [29], and that 
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serum concentrations of N-CLB are affected by CYP2C19 polymorphisms [17,18,30]. The effect of 
CYP2C19 polymorphisms on the clinical efficacy of CLB was recently described in one report of 
pediatric cases [30], but was not reported in adult patients. Moreover, information concerning the serum 
concentration range for clinically effective CLB or N-CLB is unknown. In this report, we analyzed the 
relationship between CYP2C19 polymorphisms and clinical efficacy of CLB in adult epileptic patients, 
and clarified the clinically therapeutic window of N-CLB. In our study, CLB was initiated at a low dose, 
since Kinoshita et al. [21] had observed that low-dose CLB therapy was effective in some patients, and 
was associated with fewer adverse reactions. This strategy differed from strategies used in previous 
reports investigating CLB therapy [17,18,30].  
Although the dose of CLB tended to be lower in PMs compared to that in EMs or IMs, the serum 
concentration of N-CLB and the seizure reduction rates were significantly higher in PMs (Table 1, Fig. 3). 
Indeed, the N-CLB C/D ratio and N-CLB/CLB ratio were significantly higher in PMs than in EMs or IMs 
(Fig. 1), while the CLB C/D ratio was not significantly different between the three groups. The clinical 
background (i.e. the epilepsy classification, seizure type, and the baseline seizure frequency) was not 
significantly different between the three groups. As shown in Fig. 2, concomitant drug administration did 
not significantly affect N-CLB concentrations, although the CYP inducers such as phenytoin, 
carbamazepine, or phenobarbital significantly decreased CLB concentrations. These findings suggest that 
CYP2C19 polymorphisms strongly affect N-CLB pharmacokinetics, resulting in differences in the clinical 
effectiveness of CLB. In addition, the serum concentration of N-CLB, but not CLB, was related to its 
therapeutic effect, evidenced by the fact that patients with excellent seizure control had significantly 
  14 
higher N-CLB serum concentrations (Fig. 4). 
A previous report suggested that the serum concentrations of CLB or N-CLB did not correlate with 
clinical efficacy [31]. Neels et al. suggested that the therapeutic range of CLB was 100–400 ng/mL, and 
that the serum concentrations of N-CLB were 8 times higher than serum concentrations of CLB [32]. In 
another report, the serum concentrations of CLB and N-CLB were in the order of 30−300 ng/mL and 300
−3000 ng/mL, respectively, in patients treated with therapeutic doses of CLB, although no clear 
relationships were indicated between efficacy and serum concentrations of CLB or N-CLB [33]. In the 
present study, it is noteworthy that the median serum concentration of N-CLB in patients with ≧ 90% 
seizure reduction was 1103 ng/mL, with this value being significantly higher than concentrations in 
patients with < 50% seizure reduction (570 ng/mL) and ≧ 50% seizure reduction (341 ng/mL) groups, 
as shown in Fig. 4. On the other hand, the median CLB concentrations were approximately 30–57 ng/mL 
regardless of the seizure reduction rate. Therefore, we considered that the therapeutic effect of CLB most 
likely depends on N-CLB serum concentration, with the therapeutic concentration of N-CLB being 
approximately 1100 ng/mL.  
Kinoshita et al. [21] also reported that when CLB was started with a daily dose of 2.5 mg, and the 
patients whose serum N-CLB concentrations were higher (mean ± SD, 738 ± 192 ng/mL) experienced 
better seizure control with fewer adverse reactions. This value is much lower than the serum 
concentrations of N-CLB in PMs that have been reported for doses of CLB used in previous studies. For 
example, Seo et al. [30] reported N-CLB serum concentrations of 7700 ± 6040, 2140 ± 1690, and 
920 ± 610 ng/mL (mean ± SD) in PMs, IMs, and EMs, respectively, and Kosaki et al. [18] reported 
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serum concentrations of 4806 ± 2575 ng/mL (mean ± SD) for N-CLB in PMs. Serum concentrations of 
CLB in our study (approximately 30-57 ng/mL) were also lower than concentrations published in the 
previous reports. Seo et al. [30] reported CLB serum concentrations of 140–210 ng/mL for each 
CYP2C19 phenotype, and Kosaki et al. [18] reported 130–219 ng/mL for each CYP2C19 phenotype. We 
suppose that these differences are derived from our strategy of low-dose CLB therapy; initiating with a 
low-dose of CLB (2.5mg/d) and acquiring good clinical effects with lower dose of CLB compared to 
conventional CLB therapy. In fact, the stable median CLB dose in our study was 5 mg/d, which was 
lower than in previous reports. Adverse reactions are probably reduced when lower doses of CLB are 
used, because higher serum concentrations of CLB or N-CLB have been supposed to be related to adverse 
reactions. This is one of the merits of low-dose CLB therapy.  
In this study, the frequency of occurrence of the phenotype for CYP2C19 was inconsistent with the 
Hardy-Weinberg equilibrium (Table 1), and the proportion of PMs was relatively high (34%), compared 
to the reported frequency in Asian populations (18–23%) [16]. This is possibly because, in our 
retrospective study, EMs tended to drop out more frequently than patients in other groups. Although the 
usual recommended starting dose of CLB is 10 mg/d, the starting dose of CLB set at 2.5 mg/d in our 
hospital resulted in inadequate serum concentrations of N-CLB in the CYP2C19 EMs. Therefore, the 
dosage was gradually increased. The increased CLB concentrations may have caused adverse reactions 
that necessitated withdrawal of CLB therapy. Although this study did not investigate the relationship 
between serum concentrations of CLB or N-CLB and side effects, this relationship remains to be clarified 
in a future study. In addition, the limitation of this study is the retrospective, uncontrolled design of the 
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study. The prospective, controlled design of the study including a large number of patients with similar 
kind of epilepsies is needed in the future. 
In conclusion, the efficacy of low-dose, add-on CLB therapy is significantly influenced by 
CYP2C19 polymorphisms. From a practical standpoint, it is better to start CLB at a low dose (2.5 mg/d) 
in PMs and to increase the dose aiming to achieve an N-CLB concentration of 1100 ng/mL, until the 
desired effect is acquired. Such individualized therapy, guided by an analysis of CYP2C19 
polymorphisms is warranted, because a good clinical effect without adverse reactions of CLB therapy 
would be expected in PMs.  
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Figure Legends 
Fig. 1. Effect of CYP2C19 polymorphisms on (a) the serum clobazam concentration/dose (CLB C/D) 
ratio, (b) the serum N-desmethylclobazam concentration/dose (N-CLB C/D) ratio, and (c) 
N-desmethylclobazam serum concentration/clobazam serum concentration (N-CLB/CLB) ratio. Each 
symbol represents an individual patient, and each bar shows the median. Patients were divided into three 
groups: EMs (*1/*1), IMs (*1/*2 or *1/*3), and PMs (*2/*2, *3/*3 or *2/*3). P-values were obtained 
using the Kruskal-Wallis test, followed by Dunn’s multiple comparison test. 
 
Fig. 2. Effect of co-administered drugs on serum concentrations of (a) CLB and (b) N-CLB. CYP 
inducers are phenytoin, carbamazepine, or phenobarbital. CYP2C19 inhibitors are zonisamide or 
topiramate. Each symbol represents an individual patient, and each bar shows the median. Closed circles 
indicate CYP2C19 PM, and open circles indicate CYP2C19 EM or IM. P-values were obtained using the 
Kruskal-Wallis test, followed by Dunn’s multiple comparison test. 
 
Fig. 3. Comparisons of seizure frequency before and after initiation of CLB therapy according to the 
CYP2C19 polymorphisms. P-values were obtained using the paired t- test. 
 
Fig. 4. Relationships between the seizure reduction rate and the serum concentrations of (a) CLB and (b) 
N-CLB. Each symbol represents an individual patient, and each bar shows the median. The 
concentrations of CLB and N-CLB were plotted with a logarithm scale. Closed circles indicate CYP2C19 
  23 
PM, and open circles indicate CYP2C19 EM or IM. P-values were obtained using the Kruskal-Wallis test, 
followed by Dunn’s multiple comparison test. 
  24 
Table 1. Characteristics of patients included in the study  
Characteristic EMs IMs PMs p-value 
Number of patients 11 (22%) 22 (44%) 17 (34%) < 0.01a 
Gender (M/F) 5/6 13/9 6/11 0.331b 
Age (year) 









CLB dose (mg/d) 
CLB dose/body weight 
(mg/kg/d) 
CLB conc. (ng/mL) 





















     
Epilepsy classification:     
Temporal lobe epilepsy 5 11 8 0.912b 
Extra-temporal lobe   
epilepsy 




3 8 6  
     
Seizure type:      
Complex partial 
seizures 
5 16 6 0.334b 










     
Seizure frequency at    
baseline: 
    
Intractable 9 14 14 0.190b 
Tractable 1 7 2  
     
Co-administered 
AEDs: 
    
CYP inducerd (+/-) 6/5 16/6 13/4 0.434b 
 CYP2C19 
 inhibitore (+/-) 
2/9 6/16 7/10 0.402b 
Data are shown as median (range) or number of patients    
a: Hardy-Weinberg equilibrium test for CYP2C19 phenotype    b: p-value by Chi-square test  
c: p-value by Kruskal-Wallis test   d: phenytoin, carbamazepine, or phenobarbital   
e: zonisamide or topiramate    
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